Novel immuno-oncology antigen

The term 'Novel immuno-oncology antigen' is a generic descriptive phrase used in biomedical research and drug development to refer to any newly identified protein, carbohydrate, or lipid structure that can elicit an immune response against tumor cells. It does not represent a single, specific biological entity or canonical target. Instead, it encompasses a broad range of molecules, including immune checkpoint ligands (e.g., B7-H3, TIGIT, LAG-3), cancer-testis antigens (e.g., NY-ESO-1), and patient-specific neoantigens derived from somatic mutations. These antigens are typically investigated as alternatives or adjuncts to established checkpoints like PD-1 or CTLA-4 to overcome therapeutic resistance or expand the range of treatable cancers. Because the term is a functional classification rather than a specific molecule, it lacks a unique canonical structure, a singular mechanism of action, or a defined set of interacting drugs.

Not applicable as this is a generic category of targets rather than a specific molecule.